LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・Gilead Sciences Inc.

Gilead Sciences Inc.

Abierto

Sector Salud

82.88 0.04

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

82.43

Máximo

83.26

Métricas clave
By Trading Economics
Ingresos	5.8B 1.6B
Ventas	314M 7B
P/B Media del Sector	190.58 103.001
BPA	2.01
Margen de beneficio	23.057
Empleados	18,000
EBITDA	6.5B 3B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+0.1 upside

Dividendos
By Dow Jones
Próximas Ganancias	5 nov 2024
Fecha Próximo Dividendo	27 sept 2024
Próxima Fecha de Ex Dividendo	12 dic 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	99B
Apertura anterior	82.84
Cierre anterior	82.88

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

74 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

78.6 / 83.16 Soporte y Resistencia

Gilead Sciences Inc. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

8 ago 2024, 20:49 UTC

Ganancias

Gilead Sciences Posts Higher 2Q Profit, Revenue on Increased Sales

25 abr 2024, 20:39 UTC

Ganancias

Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges

28 mar 2024, 13:35 UTC

Principales Movimientos del Mercado

Xilio Shares Take Flight Premarket After Gilead Deal

9 ago 2024, 20:12 UTC

Ganancias

Gilead Stock Dips As 'Non-Core' Products Drive Its Second-Quarter Beat -- IBD

9 ago 2024, 09:00 UTC

Principales Noticias

These Stocks Are Moving the Most Today: Expedia, Paramount, E.l.f. Beauty, Doximity, Rocket Lab, Gilead, and More -- Barrons.com

8 ago 2024, 20:03 UTC

Principales Noticias

Ganancias

Gilead Boosts Earnings Outlook as Stock Battles Back from Cancer Disappointment -- Barrons.com

8 ago 2024, 20:03 UTC

Ganancias

Gilead Sciences Sees FY24 EPS 0c-EPS 30c >GILD

8 ago 2024, 20:03 UTC

Ganancias

Gilead Sciences Sees 3Q Adj EPS $3.60-Adj EPS $3.90 >GILD

8 ago 2024, 20:02 UTC

Ganancias

Gilead Sciences 2Q Rev $7B >GILD

8 ago 2024, 20:02 UTC

Ganancias

Gilead Sciences 2Q Adj EPS $2.01 >GILD

8 ago 2024, 20:02 UTC

Ganancias

Gilead Sciences 2Q EPS $1.29 >GILD

8 ago 2024, 20:02 UTC

Ganancias

Gilead Sciences 2Q Net $1.61B >GILD

20 jun 2024, 20:16 UTC

Principales Noticias

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 jun 2024, 18:09 UTC

Principales Noticias

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 jun 2024, 16:24 UTC

Ganancias

Gilead Stock Jumps. Its Twice-Yearly Shot Prevents HIV. -- Barrons.com

20 jun 2024, 11:00 UTC

Principales Noticias

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- WSJ

25 abr 2024, 20:41 UTC

Ganancias

Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again -- IBD

25 abr 2024, 20:10 UTC

Ganancias

Gilead Sciences Cuts FY View To Adj EPS $3.45-Adj EPS $3.85 >GILD

25 abr 2024, 20:10 UTC

Ganancias

Gilead Sciences Cuts FY View To EPS 10c-EPS 50c >GILD

25 abr 2024, 20:09 UTC

Ganancias

Gilead Sciences Backs FY Product Sales $27.1B-$27.5B >GILD

25 abr 2024, 20:08 UTC

Ganancias

Gilead Closed CymaBay Acquisition Resulting in $3.9 B Acquired IPR&D Chg, or $3.14 Diluted EPS Impact

25 abr 2024, 20:07 UTC

Ganancias

Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss? -- IBD

25 abr 2024, 20:03 UTC

Principales Noticias

Ganancias

Gilead Beats Earnings Expectations After Rocky Quarter -- Barrons.com

25 abr 2024, 20:02 UTC

Ganancias

Gilead Sciences 1Q Loss $4.17B >GILD

25 abr 2024, 20:02 UTC

Ganancias

Gilead Sciences 1Q Loss/Shr $3.34 >GILD

25 abr 2024, 20:02 UTC

Ganancias

Gilead Sciences 1Q Adj Loss/Shr $1.32 >GILD

25 abr 2024, 20:02 UTC

Ganancias

Gilead Sciences 1Q Rev $6.7B >GILD

22 mar 2024, 13:18 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences Announces Completion Of Acquisition Of CymaBay >GILD CBAY

11 mar 2024, 12:26 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Other Conditions Remain to Be Satisfied, Including, Among Others, a Minimum Tender of Shrs of Common Stk of CymaBay Representing a Majority of the Total Number of Outstanding Shrs of Common Stk of CymaBay >GILD

11 mar 2024, 12:26 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Expiration of the HSR Waiting Period Satisfies One of the Conditions to Consummate the Tender Offer >GILD

Comparación entre iguales

Cambio de precio

Gilead Sciences Inc. Esperado

Precio Objetivo

By TipRanks

0.1% repunte

Estimación a 12 meses

Media 82.89 USD 0.1%

Máximo 95 USD

Mínimo 70 USD

De acuerdo con 23 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gilead Sciences Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

23 ratings

Comprar

Mantener

Vender

De acuerdo con 23 analistas que ofrecen calificaciones bursátiles a para Gilead Sciences Inc. Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

78.6 / 83.16Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

74 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gilead Sciences Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.